Innovation

into.blood

Developing

therapies.for

the.treatment

of.rare.diseases

Developing and commercializing specialized therapies for the treatment of rare diseases by using the patient’s own blood

Latest News

Our Technology

EryDel’s proprietary platform technology is an easy to use, fast and automatic bedside procedure, to encapsulate small and large molecules including therapeutic enzymes in patients’ red blood cells. The cells are immediately re-infused into patients providing prolonged half-life in circulation, reduced immunogenicity, better tolerability and predictable vascular distribution.

A late Stage
and Broad Pipeline

More details

Our People

+

Luca Benatti
Chief Executive Officer

+

Giovanni Mambrini
Chief Operating Officer

+

Ronan Gannon
Chief Commercial Officer

+

Stan Musial
Chief Financial Officer

+

Guenter R. Janhofer
Chief Medical Officer

+

Alyssa Wyant
Senior Vice President Regulatory Affairs